Genome Editing– tag –
-
CRISPR Therapeutics Demonstrates Future Potential with Casgevy Approval, Leading Gene-Editing Market Through Pipeline Diversification
Intellectia.AI USA Overview CRISPR Therapeutics has established market leadership with the FDA approval of Casgevy, its gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. In 2025, 64 patients receive... -
Avaí Bio Achieves GMP Milestone for Anti-Aging Cell Therapy; Beam Therapeutics Targets Accelerated Approval for BEAM-302; Sana Partners with Mayo Clinic for Type 1 Diabetes
Newswire.ca Canada Overview Multiple biotech companies reported significant advancements: Avaí Bio completed its GMP-grade Master Cell Bank (MCB) for the α-Klotho anti-aging program, paving the way for preclinical and clinical trials. Be... -
Sana Biotechnology to Initiate Hypoimmune Cell Therapy and In Vivo CAR T Trials This Year, with Data Expected Within 12 Months
TradingView USA Overview Sana Biotechnology is set to commence clinical trials for two key platforms this year: a hypoimmune cell therapy targeting Type 1 diabetes and an in vivo CAR T platform for oncology and autoimmune diseases. Initi... -
Intellia Therapeutics Sees Steady Progress with HAE Therapy Lonvo-Z and ATTR Amyloidosis Therapy Nex-Z; FDA Lifts Clinical Hold on Nex-Z
Seeking Alpha USA Overview Intellia Therapeutics has demonstrated steady progress in the clinical development of Lonvo-Z for hereditary angioedema (HAE) and Nex-Z for ATTR amyloidosis. Positive data reported from the Phase 3 HAELO study ... -
REPROCELL Unveils AI-Designed CRISPR for Hypoimmune iPSC Engineering, Accelerating Off-the-Shelf Cell Therapy Development
REPROCELL Japan Overview REPROCELL announced that its StemEdit platform, integrating AI-designed CRISPR with optimized workflows, has achieved high gene-editing efficiency and reduced off-target activity in induced pluripotent stem cells... -
CRISPR Gene Editing Utilized: First Leishmaniasis Vaccine Receives FDA IND Approval, Advancing to Phase 1 Clinical Trial
Ohio State News USA Overview The first leishmaniasis vaccine, developed by researchers at Ohio State University, is set to begin a Phase 1 clinical trial after receiving Investigational New Drug (IND) approval from the FDA. This innovati... -
Beam Therapeutics Stock Rises 2.04% After Receiving Triangle Business Journal’s 2026 Life Sciences Award, Signaling Heightened Market Optimism
Traders Union USA Overview Beam Therapeutics received the prestigious 2026 Life Sciences Award from Triangle Business Journal, acknowledging its innovative contributions. Concurrently, the company's stock experienced a 2.04% rise, reflec... -
High Volume of CRISPR Therapeutics Call Options Reflects Strong Market Confidence in Gene-Editing Pipeline
MarketBeat USA Overview On June 4, 2026, CRISPR Therapeutics (NASDAQ:CRSP) experienced exceptionally high call option trading volume, indicating robust investor interest in the company. This active trading reflects sustained confidence f... -
Intellia Therapeutics to Unveil Additional Phase 3 HAELO Data for Lonvo-z, a Hereditary Angioedema Therapy, at EAACI Annual Congress
Quiver Quantitative USA Overview Intellia Therapeutics announced it would present additional Phase 3 HAELO clinical trial data for lonvo-z (lonvoguran ziclumeran), its CRISPR-based gene-editing therapy for hereditary angioedema (HAE), at... -
EMA Initiates Review of Otarmeni’s Hereditary Hearing Loss Gene Therapy; Eli Lilly Announces Phase 2 Plans for VERVE-102 in Cardiovascular Disease
LucidQuest Ventures USA Overview Key developments in the cell and gene therapy sector were reported on May 28, 2026, with Otarmeni's hereditary hearing loss gene therapy entering EMA review. Eli Lilly detailed its Phase 2 clinical trial ...
